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Abstract 
Purpose: To prepare transdermal films of ketorolac tromethamine (KT) and study the effect of 
turpentine oil as a penetration enhancer for the drug.  
Methods: Transdermal films of KT were prepared with Carbopol-934 and ethyl cellulose, with turpentine 
oil as the penetration enhancer, using solvent evaporation method. The films were characterized for 
physicochemical properties, ex vivo permeation, as well as in vivo anti-inflammatory and analgesic 
activities in Wistar rats. 
Results: The transdermal films were uniform in weight and thickness, flat, with high drug content (93.9 
to 98.5 %) and of high folding endurance (134.0 to 180.0). Drug permeation through excised rat 
abdominal skin was prolonged, with the total drug release ranging from 58.88 to 88.98 % in 24 h. The 
films containing penetration enhancer showed higher drug permeation than the one without the 
enhancer; furthermore, drug permeation increased with increase in the concentration of the enhancer. 
The films were non-irritant to the skin. The transdermal films prepared with permeation enhancers 
showed greater anti-inflammatory activity (87.55 ± 2.50 and 83.24 ± 2.29 % inhibition of rat paw edema 
at the end of 12 h for formulations F2 and F3, respectively, compared to that of the formulation without 
enhancer with 69.99 %) as well as greater analgesic activity (quicker onset of analgesia in 1.5 h with 
longer duration of 10 to 12 h).  
Conclusion: Transdermal films of ketorolac have a potential for use in the treatment of pain and 
inflammation. Incorporation of turpentine oil in the films enhances not only drug flux but also analgesic 
and anti-inflammatory activities in rats. 
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Spinal cord injury (SCI) can be very devastating. 
To repair the initial tissue damage, SCI leads to 
complex cellular and molecular interactions 
within the central nervous system [1,2]. Pain and 
inflammation drastically affect the quality of life 
after SCI.  Chronic pain is a common and 
significant problem occurring after SCI. Non-
steroidal anti-inflammatory drugs (NSAIDs) are 
frequently suggested for musculoskeletal pain, 
while opioid and nonopioid analgesics are used 
for both types of pain [3].  
 
It is believed that reducing inflammation can 
decrease secondary degeneration and the 
functional deficit after SCI. The conventional 
systemic delivery of NSAIDs is generally 
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associated with the high incidence of serious 
gastrointestinal disturbances, more peripheral 
distribution (rather than the localized delivery for 
analgesia and anti-inflammatory effect) of drug 
leading to higher plasma levels and hence more 
adverse effects [4,5]. Therefore, transdermal 
drug delivery systems (TDDS) of NSAIDs are 
potential alternative measure of drug delivery 
with the added advantage of higher site specific 
delivery with low plasma concentration (leading 
to less adverse effects), circumventing of hepatic 
first pass effect, avoidance of gastric 
irritation/discomfort, no drug-drug interaction, 
prolonged drug release, controlled therapeutic 
responses and improved patient compliance [6-
8].  
 
Transdermal films/patches are a practical and 
feasible dosage form in that there is better 
patient compliance and are very suited for 
chronic pain and inflammation management in 
SCI, arthritis and other related problems. 
Transdermal delivery of drugs can be enhanced 
through use of chemical enhancers, 
iontophoresis, electroporation, ultrasound, 
microneedles, jet injection and thermal poration 
[9]. The use of various penetration enhancers 
can improve drug flux across the skin. Some 
chemicals used to improve penetration across 
the skin include alcohols, terpenes and 
surfactants [10]. Turpentine oil is one of the most 
widely investigated penetration enhancer as it 
improves the transdermal flux of a variety of 
drugs [9,10].  
 
Ketorolac tromethamine is one of the most potent 
pyrrolo-pyrrole group of NSAIDs. It inhibits both 
cyclooxygenase-1 (COX-1) and COX-2. As it has 
been suggested that COX contributes to 
ischemic neuronal damage it is evident that COX 
inhibitors may reduce spinal cord ischemic injury 
[11].  Various attempts have been made to 
improve the bioavailability of KT (t½ = 4 to 6 h) 
through various dosage forms or delivery 
systems including the transdermal drug delivery 
systems [12-15]. Therefore, the aim of the 
present study was to prepare the transdermal 
film of and determine the effect of increasing 
concentration of turpentine oil, used as 






Ketorolac tromethamine (KT), Carbopol 934 (CP-
934), Polyvinyl pyrrolidone K30 (PVP-K30), 
Polyvinyl Alcohol, carrageenan and Turpentine 
Oil were purchased from Sigma Aldrich, USA. All 
other chemicals used were of analytical grade.  
 
Preparation of transdermal films 
 
Matrix type transdermal films loaded with KT 
were prepared using solvent evaporation 
technique as per Table 1. 
 
To prepare the backing membrane, an aqueous 
solution of polyvinyl alcohol (4 % w/v) was 
poured onto cylindrical glass molds followed by 
drying at 50 °C for 4 h. 
 
Required amount of polymers (EC and Carbopol-
934) were dissolved in the dichloromethane: 
methanol (1:1) solvent in a beaker with agitation 
of about 500 rpm using a magnetic stirrer. KT, di-
n-butylphthalate (plasticizer), and turpentine oil 
(penetration enhancer) were added to the 
solution under continuous stirring. After the 
mixing, the solution was cast onto the PVA 
backing membrane on a horizontal plane and 
kept overnight to obtain a dry film. After complete 
drying, the transdermal patches of 2 × 2 cm were 
cut, wrapped in aluminum foil and stored in 
desiccator till further evaluation.  
 
Physical evaluation of films 
 
The films were evaluated for thickness, weigh 
uniformity, flatness, folding endurance and 
moisture content (Table 2). 
 
The average thickness (of three different site) of 
the film was determined using a screw-gauge 
(Mitutoyo MMO-25DS) in circular cast (n = 3). 
The weight of each patch (4 cm2) was 
determined (n = 3). 
 
Table 1: Composition of transdermal films of Ketorolac tromethamine (KT) 
 
Formulation code Ingredient 
KT* 
(% w/w) 




F1 20 2:1 30 - 
F2 20 2:1 30 0.5 
F3 20 2:1 30 1.0 
F4 20 2:1 30 2.0 
* % w/w of the total weight of polymer; ** Total weight of polymers taken was 500 mg 
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To assess the flatness of the prepared films, 
longitudinal strips were cut from three different 
location of the each film. The length of each strip 
after waiting for 2 h was measured and the 
variation if any was noted.  The variation in 
length indicates the nonuniformity in flatness. 
Non-uniformity or constriction was calculated as 
in Eq 1.  
 
Constriction (%) = {(L1 - L2) / L1}100 ..…. (1) 
 
where L1 is the initial length of each strip and L2 
is the final length of each strip.  
 
Flatness was calculated as in Eq 2.  
 
Flatness (%) = (100 – % constriction) …….. (2)  
 
Folding endurance was determined by 
repeatedly folding a small strip of size (2 × 2 cm) 
of film at the same point until it broke. The films 
were first exposed to 84 % relative humidity, and 
moisture content determined for all the films by 
weighing the film samples individually and kept in 
a desiccator containing activated silica at room 
temperature for 24 h. Individual films were 
weighed repeatedly until they attained constant 
weight. Moisture content was calculated as the 
difference between initial and final weight with 





Patch from each film was dissolved in 100 mL 
methanol with continuous stirring for 2 h (n = 3). 
The solutions were filtered, diluted suitably and 
analyzed at 322 nm in a UV spectrophotometer 
(Shimadzu, UV-150-02, Seisakusho, Ltd., Kyoto, 
Japan) (Table 2). 
 
Scanning electron microscopy 
 
To assess surface morphology, SEM of the films 
were performed by scanning electron microscope 
(JEOL JSM 5600, Japan). A sample of the film 
was affixed on the mold and the SEM operated 
at 15 V. 
 
Ex vivo permeation studies 
 
The ex vivo permeation studies of the films of KT 
through an excised rat abdominal skin treated 
before the experiment by trimming to clean the 
connective tissues and then washing with 
isotonic buffer pH 7.4 buffer. The experiment was 
carried out using a modified Franz diffusion cell. 
A patch of 4.0 cm2 of each formulation under 
study was placed in intimate contact with the 
excised skin. The receptor compartment of the 
diffusion cell was filled with 25 mL (such that it 
remained in touch with the excised skin placed at 
the junction of donor and receptor 
compartments) of pH 7.4 phosphate buffer 
(containing a magnetic stirrer rotating at 100 rpm; 
kept at 37 ± 1 oC by means of a water jacket 
around the diffusion cell). Samples (1 mL each) 
were withdrawn at different time intervals, 
filtered, diluted suitably and then analyzed using 
UV spectrophotometer at 322 nm. The withdrawn 
sample was replaced on each occasion with an 
equal volume of fresh medium.  
 
In vivo studies 
 
Healthy male Wistar rats (200-250 g) were used 
in the studies. The rats were kept in cages in 
standard environmental conditions of light and 
temperature. The rats were allowed free access 
to drinking water and standard diet. The 
protocols of the animal study were approved by 
the Institutional Animal Care and Use Committee 
of Linzi People’s Hospital (approval ref no. 
20160611) and was carried out in compliance 
with the Directive 2010/63/EU on the handling of 
animals used for scientific purposes [16]. 
 
Primary skin irritancy  
 
To assess the irritant effect or any chance of 
edema with the use of transdermal patches, 
primary skin irritancy test was performed. The 
healthy male rats (200 - 250 g) were divided into 
four groups of three rats each. A 5 cm2 area of 
dorsal portion of all the rats were shaved and 
cleaned with spirit. After 12 h post shaving, the 
non-medicated patch was applied to group I 
(control) using an adhesive tape USP. To group 
II and III (both test) transdermal patch 
formulation F3 and F5 were applied. To group IV 
(standard), 0.8 % v/v aqueous solution of 
formaldehyde (irritant) was applied. The 
application sites were observed for any erythema 
and edema on skin surface for 7 days after 
application and the scoring was done (0 for none, 
1 for slight, 2 for well defined, 3 for moderate and 
4 for scar formation in case of erythema and 0 for 
none, 1 for slight, 2 for well defined, 3 for 
moderate and 4 for severe in case of edema). 
[17,18]. 
 
In vivo anti-inflammatory test 
 
The selected formulations were subjected to in 
vivo anti-inflammatory test using standard 
carrageenan-induced hind rat paw edema model.  
Rats were divided into four groups of three rats 
each. The dorsal surface of rats was shaved 12 h 
before commencing the study. Control group 
(group I) received non-medicated (blank) 
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patches. To groups II and III, patches F3 and F5 
were applied on the dorsal sides of the rats while 
group IV received the F1 (plain patch with drug 
but without penetration enhancer). To induce the 
paw edema, after half an hour of the application 
of patches, all the rats were injected (subplantar) 
with 0.1 mL of a 1 % w/v homogeneous 
suspension of carrageenan (in double-distilled 
water) in the right paws. The hind paw volume 
was measured immediately (0 h) and at different 
time intervals, using a plethysmometer (Model 
7150, UGO Basile, Italy), and expressed as 
percent edema relative to the initial hind paw 
volume. Inhibition of edema was calculated as in 
Eq 3.  
 
Inhibition (%) = Ec – Et)/Ec}100 ……………. (3) 
 
where Ec is % edema in control  and Et is % 
edema in test. 
 
In vivo analgesic activity  
 
The rats were placed on hot plate 
analgesiometer (MK-350 D, Japan) at 50 ± 1 °C. 
The transdermal film was placed on the shaved 
dorsal surface of rat with KT dose (1.0 mg/kg) 
thirty min before the beginning of the test. The 
time taken till the rat begins to jump or lick 
forepaw was determined and this time was called 





The results are expressed as mean ± standard 
deviation. Statistical analysis was carried out 
using analysis of variance (ANOVA; one way 
between groups and parametric ANOVA) with 
the aid of GraphPad Prism© 4.0 (Graphpad 
Software Inc. San Diego, CA, USA). P < 0.05 




Physicochemical properties of the prepared 
films 
 
The thickness, weight, folding endurance, % 
moisture content and drug content of the 
prepared transdermal patches were determined 
(Table 2). 
 
All the transdermal films showed uniform 
thickness ranging from 0.247 ± 0.022 to 0.310 ± 
0.012 mm. Weight of patches (area - 4 cm2) of 
different formulations ranged from 115 ± 0.24 to 
125 ± 0.48 mg. Due to lack of any constriction in 
any of the films, it was inferred that all the films 
were 100 % flat. Folding endurance ranged from 
134.0 ± 8.72 to 180.0 ± 8.10. Percent moisture 
content ranged from 2.92 ± 0.20 to 9.46 ± 0.42. 
The formulations with penetration enhancers 
showed higher moisture content and the highest 
moisture was observed in the films having 
highest proportion of turpentine oil.  
 
Drug loading  
 
All the transdermal films showed high and 
uniform drug loading. The percentage drug 
content ranged from 93.90 ± 2.90 to 98.50 ± 1.60 




The SEM of the transdermal films (Fig 1) showed 
that drug was uniformly dispersed in the matrix of 
the film with some projections of drug particles 
on the surface of film. No difference was 
observed in the SEM of different formulations. 
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(a)             (b)  
 
Figure 1: SEM of transdermal films of KT prepared with EC and CP-934 (a) Formulation F1 prepared without 
penetration enhancer (F1) and; (b) Formulation F3 prepared with penetration enhancer (turpentine oil) 
 
Drug release through excised skin  
 
The films prepared with penetration enhancer F2, 
F3 and F4 showed greater percent drug release 
at the end of 24 h (Fig 2). The drug permeation 
was prolonged with the transdermal film 
formulations prepared with turpentine oil as 
penetration enhancer. The permeation 
enhancement effect was highest for F4. However 
it was also observed that there was no significant 
difference in penetration enhancement between 
the transdermal films F3 and F4. The cumulative 
% drug permeated at the end of 24 h was found 
to be 58.88, 71.22, 87.09, and 88.98 % for F1, 




Figure 2: Ex vivo permeation study through rat 
abdominal skin of transdermal films of Ketorolac of F1 
(●); F2 (□); F3 (Δ) and F4 (×) 
 
Skin irritation effect 
 
The prepared film formulations F1 (without 
enhancer) and F4 (with highest concentration of 
enhancer) were selected for the study. Both the 
formulations were found to be non-irritant to the 
skin because it showed erythema and edema 
score less than 2 [17,18]. 
 
In vivo anti-inflammatory activity 
 
The results showed that the patches prepared 
with penetration enhancers (F2 and F3) showed 
greater percent inhibition as compared to that of 
F1 (without penetration enhancer). The 
transdermal films showed 87.55 ± 2.50 and 
83.24 ± 2.29 % inhibition of rat paw edema at the 
end of 12 h for formulation F2 and F3, 
respectively as compared to that of formulation 
without enhancer (F1) with 69.99 % only (Fig. 3). 
 
In vivo analgesic activity 
 
The maximum response (MR) to KT in terms of 
the reaction time in seconds which reflects the 
intensity of drug action; the time of the maximum 
response (TMR) and; the duration of drug action 
(DA) are shown in Table 4. 
 
It was observed that F2 and F3 showed greater 
analgesic activity than F1. F2 and F3 (with 
permeation enhancer) showed faster onset of 
analgesia in 1.5 h with longer duration for 10 to 
12 h. It was also evident that analgesic activity 
was followed the same trend as the anti-
inflammatory activity of the formulation. 
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Group II 
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3 ± 0 1.67±0.5
0 
a P < 0.05, significant compared with formalin; * Erythema scale: 0, none; 1, slight; 2, well defined; 3, moderate; 




Figure 3: In vivo anti-inflammatory activity of the transdermal films of ketorolac tromethamine using carrageenan 
induced hind rat paw edema model. (p < 0.05, significant compared with control; Values corresponding to 4 to12 
h were significant as compared to control; n = 3) 
 
Table 4: In vivo analgesic activity of transdermal films of KT by hot plate method 
 
Formulation Maximum analgesic response  
MR (s) 
Time of maximum 
analgesic response 
TMR (h) 
Duration of analgesic 
action  
DA (h) 
F1 12.5±2.02 2 6 
F2 10.5±1.26  1.5 >10 
F3 8.6±1.02 1.5 >12 




In patients with SCI, often only parenteral 
products can be administered to the patients. 
Even if the patient can take oral medication, 
delivering the drug in transdermal films increases 
the patient compliance with the added advantage 
of immediate and prolonged release of the drug 
for the effective treatment of pain and 
inflammation.  
 
In this study transdermal films of KT were 
prepared with the aim of delivering the drugs to 
localized area of inflammation directly and 
avoiding the systemic side effects of the drug. 
Clinically feasible high loading of drug was 
obtained in all the films.  
 
SEM photographs confirmed that for the initial 
drug release the surface drug might have played 
the role. The subsequent slow and prolonged 
release was from the drug present in the matrix 
of the film. The transdermal films prolonged drug 
release (up to 24 h) thereby minimizing dosage 
frequency unlike the conventional oral drug 
delivery. The use of a single patch for the whole 
day is expected to be more patient friendly as 
compared to the frequent oral dosing of tablets. 
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Out of these various methods of transdermal 
enhancement of drugs chemical enhancers has 
been reported to be the best in increasing the 
transport across the skin [9,10]. In the present 
study the turpentine oil increased the permeation 
very significantly. The increase was directly 
proportional to the concentration of turpentine oil 
and it was in good agreement with previous 
studies [9,17,19]. Previous studies have also 
reported the turpentine oil and the terpene based 
enhancers as the very promising penetration 
enhancer with the greater effect of increasing the 
flux and anti-inflammatory activity [9,20-22]. The 
present study also found turpentine oil as an 
effective penetration enhancer for the 
transdermal drug delivery of KT in the in vivo 
anti-inflammatory and analgesic activity both for 
the films with penetration enhancers (F2 and F3) 
as compared to that of films without enhancer 
(F1) [12,23]. The increasing concentration 
showed increased flux and increased analgesic 
and anti-inflammatory activity. Formulations with 
permeation enhancer showed more rapid onset 
(1.5 h) and longer duration of analgesia (for 10 to 
12 h). These data correlate well with ex vivo 
permeation data. Thus, the enhanced 
permeation of the drug across the skin produced 
greater analgesic and anti-inflammatory activities 




The developed transdermal film of KT has a 
great potential for the management of pain and 
inflammation associated with SCI. The 
transdermal films of KT can deliver therapeutic 
concentrations of the drug in a steady and 
prolonged manner throughout the day. 
Turpentine oil is a good penetration enhancer 
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